

---

[Avner Ingerman](#), MD, MSc, brings over 25 years of clinical ophthalmology and industry experience in drug and device development. His areas of expertise include regulatory strategy development, clinical program design and clinical operations, medical monitoring, scientific advisory boards, clinician community interactions and assessment of opportunities in ophthalmology. He has a proven track record of drug development from phase I-IV as well as regulatory experience with EU, FDA, and Japan.

Dr. Ingerman received his MD and MSc. from the Sackler school of Medicine at Tel-Aviv University. He is experienced in front and back-of-the-eye indications, novel therapies (gene and cell therapies), delivery modes, and ocular safety.

Dr. Ingerman's clinical development programs led to approvals of Alcaftadine (Lastacaft™) and Aflibercept (Eylea™). He served as the interim CMO at Achillion Pharmaceuticals, CCO at Ohr Pharmaceuticals, VP of Retina business at ORA, VP and head of Ophthalmology at Regeneron Pharmaceuticals and Senior Director of Clinical Development at Johnson and Johnson as well as R&D and Medical Affairs Director at JNJ. His executive leadership solidified his strong understanding of the pharmaceutical industry with experience in the US and international clinical and business development, funding strategies and investment community interactions. Dr. Ingerman also led studies in hematology, oncology, gastroenterology, neurology, psychiatry, pain management and endocrinology.